Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,982
archived clinical trials in
Endocrine

PK/PD Study With G-Pump (Glucagon Infusion) in T1DM Patients
Comparison of Pharmacokinetic and Pharmacodynamic Profiles of G-Pump™ (Glucagon Infusion) vs. GlucaGen® Delivered Subcutaneously to Subjects With Type 1 Diabetes (T1DM)
Status: Enrolling
Updated:  3/10/2018
Oregon Health and Science University
mi
from
Portland, OR
PK/PD Study With G-Pump (Glucagon Infusion) in T1DM Patients
Comparison of Pharmacokinetic and Pharmacodynamic Profiles of G-Pump™ (Glucagon Infusion) vs. GlucaGen® Delivered Subcutaneously to Subjects With Type 1 Diabetes (T1DM)
Status: Enrolling
Updated: 3/10/2018
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
Safety and Efficacy Study of Mini-Dose Glucagon (G-Pen Mini) in Patients With Type 1 Diabetes
A Randomized, Phase 2a, Blinded, 3-Way Crossover Dose-Ranging Study With G-Pen Mini™ (Glucagon Injection) to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Patients With Type 1 Diabetes Mellitus (T1DM)
Status: Enrolling
Updated:  3/10/2018
Baylor College of Medicine, Children's Nutritional Research Center, Texas Children's Hospital
mi
from
Houston, TX
Safety and Efficacy Study of Mini-Dose Glucagon (G-Pen Mini) in Patients With Type 1 Diabetes
A Randomized, Phase 2a, Blinded, 3-Way Crossover Dose-Ranging Study With G-Pen Mini™ (Glucagon Injection) to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Patients With Type 1 Diabetes Mellitus (T1DM)
Status: Enrolling
Updated: 3/10/2018
Baylor College of Medicine, Children's Nutritional Research Center, Texas Children's Hospital
mi
from
Houston, TX
Click here to add this to my saved trials
Dietary Fatty Acid Composition and Obesity-related Metabolic Abnormalities
Assessing the Effects of Two Diets Enriched in Either Saturated or Unsaturated Fatty Acids to Determine the Cellular and Molecular Mechanisms in Insulin Sensitivity
Status: Enrolling
Updated:  3/12/2018
Michigan Clincal Research Unit
mi
from
Ann Arbor, MI
Dietary Fatty Acid Composition and Obesity-related Metabolic Abnormalities
Assessing the Effects of Two Diets Enriched in Either Saturated or Unsaturated Fatty Acids to Determine the Cellular and Molecular Mechanisms in Insulin Sensitivity
Status: Enrolling
Updated: 3/12/2018
Michigan Clincal Research Unit
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Home Testing of Day and Night Closed Loop With Pump Suspend Feature
An Open-label, Multi-centre, Randomised, Single-period, Parallel Design Study to Assess the Efficacy, Safety, Utility and Psychosocial Effect of 12 Week Day and Night Automated Closed Loop Glucose Control Combined With Pump Suspend Feature Compared to Sensor Augmented Insulin Pump Therapy in Youth and Adults With Type 1 Diabetes With Sub-optimal Glucose Control Under Free Living Conditions
Status: Enrolling
Updated:  3/12/2018
University of Colorado Denver
mi
from
Aurora, CO
Home Testing of Day and Night Closed Loop With Pump Suspend Feature
An Open-label, Multi-centre, Randomised, Single-period, Parallel Design Study to Assess the Efficacy, Safety, Utility and Psychosocial Effect of 12 Week Day and Night Automated Closed Loop Glucose Control Combined With Pump Suspend Feature Compared to Sensor Augmented Insulin Pump Therapy in Youth and Adults With Type 1 Diabetes With Sub-optimal Glucose Control Under Free Living Conditions
Status: Enrolling
Updated: 3/12/2018
University of Colorado Denver
mi
from
Aurora, CO
Click here to add this to my saved trials
Home Testing of Day and Night Closed Loop With Pump Suspend Feature
An Open-label, Multi-centre, Randomised, Single-period, Parallel Design Study to Assess the Efficacy, Safety, Utility and Psychosocial Effect of 12 Week Day and Night Automated Closed Loop Glucose Control Combined With Pump Suspend Feature Compared to Sensor Augmented Insulin Pump Therapy in Youth and Adults With Type 1 Diabetes With Sub-optimal Glucose Control Under Free Living Conditions
Status: Enrolling
Updated:  3/12/2018
International Diabetes Center-Park Nicollet
mi
from
Minneapolis, MN
Home Testing of Day and Night Closed Loop With Pump Suspend Feature
An Open-label, Multi-centre, Randomised, Single-period, Parallel Design Study to Assess the Efficacy, Safety, Utility and Psychosocial Effect of 12 Week Day and Night Automated Closed Loop Glucose Control Combined With Pump Suspend Feature Compared to Sensor Augmented Insulin Pump Therapy in Youth and Adults With Type 1 Diabetes With Sub-optimal Glucose Control Under Free Living Conditions
Status: Enrolling
Updated: 3/12/2018
International Diabetes Center-Park Nicollet
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Home Testing of Day and Night Closed Loop With Pump Suspend Feature
An Open-label, Multi-centre, Randomised, Single-period, Parallel Design Study to Assess the Efficacy, Safety, Utility and Psychosocial Effect of 12 Week Day and Night Automated Closed Loop Glucose Control Combined With Pump Suspend Feature Compared to Sensor Augmented Insulin Pump Therapy in Youth and Adults With Type 1 Diabetes With Sub-optimal Glucose Control Under Free Living Conditions
Status: Enrolling
Updated:  3/12/2018
International Diabetes Centre at Park Nicollet
mi
from
Minneapolis, MN
Home Testing of Day and Night Closed Loop With Pump Suspend Feature
An Open-label, Multi-centre, Randomised, Single-period, Parallel Design Study to Assess the Efficacy, Safety, Utility and Psychosocial Effect of 12 Week Day and Night Automated Closed Loop Glucose Control Combined With Pump Suspend Feature Compared to Sensor Augmented Insulin Pump Therapy in Youth and Adults With Type 1 Diabetes With Sub-optimal Glucose Control Under Free Living Conditions
Status: Enrolling
Updated: 3/12/2018
International Diabetes Centre at Park Nicollet
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Home Testing of Day and Night Closed Loop With Pump Suspend Feature
An Open-label, Multi-centre, Randomised, Single-period, Parallel Design Study to Assess the Efficacy, Safety, Utility and Psychosocial Effect of 12 Week Day and Night Automated Closed Loop Glucose Control Combined With Pump Suspend Feature Compared to Sensor Augmented Insulin Pump Therapy in Youth and Adults With Type 1 Diabetes With Sub-optimal Glucose Control Under Free Living Conditions
Status: Enrolling
Updated:  3/12/2018
University of Cambridge
mi
from
Cambridge,
Home Testing of Day and Night Closed Loop With Pump Suspend Feature
An Open-label, Multi-centre, Randomised, Single-period, Parallel Design Study to Assess the Efficacy, Safety, Utility and Psychosocial Effect of 12 Week Day and Night Automated Closed Loop Glucose Control Combined With Pump Suspend Feature Compared to Sensor Augmented Insulin Pump Therapy in Youth and Adults With Type 1 Diabetes With Sub-optimal Glucose Control Under Free Living Conditions
Status: Enrolling
Updated: 3/12/2018
University of Cambridge
mi
from
Cambridge,
Click here to add this to my saved trials
Validation of Macimorelin as a Test for Adult Growth Hormone Deficiency
Confirmatory Validation of Oral Macimorelin as a Growth Hormone (GH) Stimulation Test (ST) for the Diagnosis of Adult Growth Hormone Deficiency (AGHD) in Comparison With the Insulin Tolerance Test (ITT)
Status: Enrolling
Updated:  3/13/2018
Texas Diabetes & Endocrinology, PA
mi
from
Austin, TX
Validation of Macimorelin as a Test for Adult Growth Hormone Deficiency
Confirmatory Validation of Oral Macimorelin as a Growth Hormone (GH) Stimulation Test (ST) for the Diagnosis of Adult Growth Hormone Deficiency (AGHD) in Comparison With the Insulin Tolerance Test (ITT)
Status: Enrolling
Updated: 3/13/2018
Texas Diabetes & Endocrinology, PA
mi
from
Austin, TX
Click here to add this to my saved trials
Validation of Macimorelin as a Test for Adult Growth Hormone Deficiency
Confirmatory Validation of Oral Macimorelin as a Growth Hormone (GH) Stimulation Test (ST) for the Diagnosis of Adult Growth Hormone Deficiency (AGHD) in Comparison With the Insulin Tolerance Test (ITT)
Status: Enrolling
Updated:  3/13/2018
Harbor UCLA Medical Center
mi
from
Torrance, CA
Validation of Macimorelin as a Test for Adult Growth Hormone Deficiency
Confirmatory Validation of Oral Macimorelin as a Growth Hormone (GH) Stimulation Test (ST) for the Diagnosis of Adult Growth Hormone Deficiency (AGHD) in Comparison With the Insulin Tolerance Test (ITT)
Status: Enrolling
Updated: 3/13/2018
Harbor UCLA Medical Center
mi
from
Torrance, CA
Click here to add this to my saved trials
Validation of Macimorelin as a Test for Adult Growth Hormone Deficiency
Confirmatory Validation of Oral Macimorelin as a Growth Hormone (GH) Stimulation Test (ST) for the Diagnosis of Adult Growth Hormone Deficiency (AGHD) in Comparison With the Insulin Tolerance Test (ITT)
Status: Enrolling
Updated:  3/13/2018
Baylor College of Medicine-Endocrinology
mi
from
Houston, TX
Validation of Macimorelin as a Test for Adult Growth Hormone Deficiency
Confirmatory Validation of Oral Macimorelin as a Growth Hormone (GH) Stimulation Test (ST) for the Diagnosis of Adult Growth Hormone Deficiency (AGHD) in Comparison With the Insulin Tolerance Test (ITT)
Status: Enrolling
Updated: 3/13/2018
Baylor College of Medicine-Endocrinology
mi
from
Houston, TX
Click here to add this to my saved trials
Validation of Macimorelin as a Test for Adult Growth Hormone Deficiency
Confirmatory Validation of Oral Macimorelin as a Growth Hormone (GH) Stimulation Test (ST) for the Diagnosis of Adult Growth Hormone Deficiency (AGHD) in Comparison With the Insulin Tolerance Test (ITT)
Status: Enrolling
Updated:  3/13/2018
VA Puget Sound Health Care System
mi
from
Seattle, WA
Validation of Macimorelin as a Test for Adult Growth Hormone Deficiency
Confirmatory Validation of Oral Macimorelin as a Growth Hormone (GH) Stimulation Test (ST) for the Diagnosis of Adult Growth Hormone Deficiency (AGHD) in Comparison With the Insulin Tolerance Test (ITT)
Status: Enrolling
Updated: 3/13/2018
VA Puget Sound Health Care System
mi
from
Seattle, WA
Click here to add this to my saved trials
Validation of Macimorelin as a Test for Adult Growth Hormone Deficiency
Confirmatory Validation of Oral Macimorelin as a Growth Hormone (GH) Stimulation Test (ST) for the Diagnosis of Adult Growth Hormone Deficiency (AGHD) in Comparison With the Insulin Tolerance Test (ITT)
Status: Enrolling
Updated:  3/13/2018
Swedish Medical Center - Cherry Hill
mi
from
Seattle, WA
Validation of Macimorelin as a Test for Adult Growth Hormone Deficiency
Confirmatory Validation of Oral Macimorelin as a Growth Hormone (GH) Stimulation Test (ST) for the Diagnosis of Adult Growth Hormone Deficiency (AGHD) in Comparison With the Insulin Tolerance Test (ITT)
Status: Enrolling
Updated: 3/13/2018
Swedish Medical Center - Cherry Hill
mi
from
Seattle, WA
Click here to add this to my saved trials
Validation of Macimorelin as a Test for Adult Growth Hormone Deficiency
Confirmatory Validation of Oral Macimorelin as a Growth Hormone (GH) Stimulation Test (ST) for the Diagnosis of Adult Growth Hormone Deficiency (AGHD) in Comparison With the Insulin Tolerance Test (ITT)
Status: Enrolling
Updated:  3/13/2018
Krankenanstalt Rudolfstiftung
mi
from
Vienna,
Validation of Macimorelin as a Test for Adult Growth Hormone Deficiency
Confirmatory Validation of Oral Macimorelin as a Growth Hormone (GH) Stimulation Test (ST) for the Diagnosis of Adult Growth Hormone Deficiency (AGHD) in Comparison With the Insulin Tolerance Test (ITT)
Status: Enrolling
Updated: 3/13/2018
Krankenanstalt Rudolfstiftung
mi
from
Vienna,
Click here to add this to my saved trials
Vitamin D Repletion in Primary Hyperparathyroidism
Randomized Controlled Trial of Vitamin D Repletion Regimens in Primary Hyperparathyroidism
Status: Enrolling
Updated:  3/15/2018
Columbia University Medical Center
mi
from
New York, NY
Vitamin D Repletion in Primary Hyperparathyroidism
Randomized Controlled Trial of Vitamin D Repletion Regimens in Primary Hyperparathyroidism
Status: Enrolling
Updated: 3/15/2018
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
A Study of Strawberries and Disease Risk
Effect of Strawberry on Oxidative Stress- and Inflammatory-mediated Insulin Resistance (IR) in Humans: Combating a Major Risk Factor for Diabetes and Cardiovascular Disease Through Diet
Status: Enrolling
Updated:  3/15/2018
Clinical Nutrition Research Center
mi
from
Chicago, IL
A Study of Strawberries and Disease Risk
Effect of Strawberry on Oxidative Stress- and Inflammatory-mediated Insulin Resistance (IR) in Humans: Combating a Major Risk Factor for Diabetes and Cardiovascular Disease Through Diet
Status: Enrolling
Updated: 3/15/2018
Clinical Nutrition Research Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Comparison of Time-Restricted Feeding Versus Grazing
Time-Restricted Feeding to Improve Glucose Tolerance and Vascular Condition
Status: Enrolling
Updated:  3/15/2018
Pennington Biomedical Research Center
mi
from
Baton Rouge, LA
Comparison of Time-Restricted Feeding Versus Grazing
Time-Restricted Feeding to Improve Glucose Tolerance and Vascular Condition
Status: Enrolling
Updated: 3/15/2018
Pennington Biomedical Research Center
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
Assessing Neurocognitive Effects of Gluten Exposure
An Assessment of Neurocognitive Symptoms After Gluten Exposure in Adult Patients With Celiac Disease - a Pilot Study
Status: Enrolling
Updated:  3/16/2018
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Assessing Neurocognitive Effects of Gluten Exposure
An Assessment of Neurocognitive Symptoms After Gluten Exposure in Adult Patients With Celiac Disease - a Pilot Study
Status: Enrolling
Updated: 3/16/2018
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Celiac Disease Screening
A Prospective Trial of Celiac Disease Screening
Status: Enrolling
Updated:  3/16/2018
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Celiac Disease Screening
A Prospective Trial of Celiac Disease Screening
Status: Enrolling
Updated: 3/16/2018
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Celiac Disease Screening
A Prospective Trial of Celiac Disease Screening
Status: Enrolling
Updated:  3/16/2018
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Celiac Disease Screening
A Prospective Trial of Celiac Disease Screening
Status: Enrolling
Updated: 3/16/2018
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Immune Response in Celiac Disease on In-vitro Gluten Challenge
An In-vitro Gluten Challenge on the Immunologic Response in Celiac Disease.
Status: Enrolling
Updated:  3/16/2018
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Immune Response in Celiac Disease on In-vitro Gluten Challenge
An In-vitro Gluten Challenge on the Immunologic Response in Celiac Disease.
Status: Enrolling
Updated: 3/16/2018
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Clinical Evaluation of i-STAT Analyzer Glucose, Hematocrit and Sodium for Capillary Samples
Clinical Evaluation of i-STAT Analyzer for Glucose, Hematocrit and Sodium
Status: Enrolling
Updated:  3/16/2018
Diablo Clinical Research Inc
mi
from
Walnut creek, CA
Clinical Evaluation of i-STAT Analyzer Glucose, Hematocrit and Sodium for Capillary Samples
Clinical Evaluation of i-STAT Analyzer for Glucose, Hematocrit and Sodium
Status: Enrolling
Updated: 3/16/2018
Diablo Clinical Research Inc
mi
from
Walnut creek, CA
Click here to add this to my saved trials
Clinical Evaluation of i-STAT Analyzer Glucose, Hematocrit and Sodium for Capillary Samples
Clinical Evaluation of i-STAT Analyzer for Glucose, Hematocrit and Sodium
Status: Enrolling
Updated:  3/16/2018
Kentucky Clinical Trials Laboratory
mi
from
Louisville, KY
Clinical Evaluation of i-STAT Analyzer Glucose, Hematocrit and Sodium for Capillary Samples
Clinical Evaluation of i-STAT Analyzer for Glucose, Hematocrit and Sodium
Status: Enrolling
Updated: 3/16/2018
Kentucky Clinical Trials Laboratory
mi
from
Louisville, KY
Click here to add this to my saved trials
Clinical Evaluation of i-STAT Analyzer Glucose, Hematocrit and Sodium for Capillary Samples
Clinical Evaluation of i-STAT Analyzer for Glucose, Hematocrit and Sodium
Status: Enrolling
Updated:  3/16/2018
Cleveland Clinic
mi
from
Cleveland, OH
Clinical Evaluation of i-STAT Analyzer Glucose, Hematocrit and Sodium for Capillary Samples
Clinical Evaluation of i-STAT Analyzer for Glucose, Hematocrit and Sodium
Status: Enrolling
Updated: 3/16/2018
Cleveland Clinic
mi
from
Cleveland, OH
Click here to add this to my saved trials
A Study of ATR-101 for the Treatment of Congenital Adrenal Hyperplasia
A Phase 2, Multicenter Study of ATR-101 for the Treatment of Congenital Adrenal Hyperplasia
Status: Enrolling
Updated:  3/20/2018
Johns Hopkins University
mi
from
Baltimore, MD
A Study of ATR-101 for the Treatment of Congenital Adrenal Hyperplasia
A Phase 2, Multicenter Study of ATR-101 for the Treatment of Congenital Adrenal Hyperplasia
Status: Enrolling
Updated: 3/20/2018
Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Study of ATR-101 for the Treatment of Congenital Adrenal Hyperplasia
A Phase 2, Multicenter Study of ATR-101 for the Treatment of Congenital Adrenal Hyperplasia
Status: Enrolling
Updated:  3/20/2018
National Institutes of Health Clinical Center
mi
from
Bethesda, MD
A Study of ATR-101 for the Treatment of Congenital Adrenal Hyperplasia
A Phase 2, Multicenter Study of ATR-101 for the Treatment of Congenital Adrenal Hyperplasia
Status: Enrolling
Updated: 3/20/2018
National Institutes of Health Clinical Center
mi
from
Bethesda, MD
Click here to add this to my saved trials
A Study of ATR-101 for the Treatment of Congenital Adrenal Hyperplasia
A Phase 2, Multicenter Study of ATR-101 for the Treatment of Congenital Adrenal Hyperplasia
Status: Enrolling
Updated:  3/20/2018
University of Michigan
mi
from
Ann Arbor, MI
A Study of ATR-101 for the Treatment of Congenital Adrenal Hyperplasia
A Phase 2, Multicenter Study of ATR-101 for the Treatment of Congenital Adrenal Hyperplasia
Status: Enrolling
Updated: 3/20/2018
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
A Study of ATR-101 for the Treatment of Congenital Adrenal Hyperplasia
A Phase 2, Multicenter Study of ATR-101 for the Treatment of Congenital Adrenal Hyperplasia
Status: Enrolling
Updated:  3/20/2018
Mayo Clinic Rochester
mi
from
Rochester, MN
A Study of ATR-101 for the Treatment of Congenital Adrenal Hyperplasia
A Phase 2, Multicenter Study of ATR-101 for the Treatment of Congenital Adrenal Hyperplasia
Status: Enrolling
Updated: 3/20/2018
Mayo Clinic Rochester
mi
from
Rochester, MN
Click here to add this to my saved trials
A Study of ATR-101 for the Treatment of Congenital Adrenal Hyperplasia
A Phase 2, Multicenter Study of ATR-101 for the Treatment of Congenital Adrenal Hyperplasia
Status: Enrolling
Updated:  3/20/2018
The University of Oklahoma - Tulsa Schusterman Center
mi
from
Tulsa, OK
A Study of ATR-101 for the Treatment of Congenital Adrenal Hyperplasia
A Phase 2, Multicenter Study of ATR-101 for the Treatment of Congenital Adrenal Hyperplasia
Status: Enrolling
Updated: 3/20/2018
The University of Oklahoma - Tulsa Schusterman Center
mi
from
Tulsa, OK
Click here to add this to my saved trials
A Study of ATR-101 for the Treatment of Congenital Adrenal Hyperplasia
A Phase 2, Multicenter Study of ATR-101 for the Treatment of Congenital Adrenal Hyperplasia
Status: Enrolling
Updated:  3/20/2018
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
A Study of ATR-101 for the Treatment of Congenital Adrenal Hyperplasia
A Phase 2, Multicenter Study of ATR-101 for the Treatment of Congenital Adrenal Hyperplasia
Status: Enrolling
Updated: 3/20/2018
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Motivation-Audit-Positive Psychology Intervention Study
Developing a Group-based Positive Psychology and Physical Activity Intervention in Patients With Metabolic Syndrome: Qualitative Research Phase
Status: Enrolling
Updated:  3/20/2018
Massachusetts General Hospital
mi
from
Boston, MA
Motivation-Audit-Positive Psychology Intervention Study
Developing a Group-based Positive Psychology and Physical Activity Intervention in Patients With Metabolic Syndrome: Qualitative Research Phase
Status: Enrolling
Updated: 3/20/2018
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Sucralose, Stevia, Gut Microbiome and Glucose Metabolism
Sucralose, Stevia, Gut Microbiome and Glucose Metabolism
Status: Enrolling
Updated:  3/21/2018
ECRC
mi
from
Minneapolis, MN
Sucralose, Stevia, Gut Microbiome and Glucose Metabolism
Sucralose, Stevia, Gut Microbiome and Glucose Metabolism
Status: Enrolling
Updated: 3/21/2018
ECRC
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Effects of a Standardized Freeze-dried Grape Powder on High Density Lipoprotein (HDL) Function in Metabolic Syndrome
Pilot Study: Effects of a Standardized Freeze-dried Grape Powder on High Density Lipoprotein (HDL) Function in Metabolic Syndrome
Status: Enrolling
Updated:  3/22/2018
University of Connecticut
mi
from
Storrs, CT
Effects of a Standardized Freeze-dried Grape Powder on High Density Lipoprotein (HDL) Function in Metabolic Syndrome
Pilot Study: Effects of a Standardized Freeze-dried Grape Powder on High Density Lipoprotein (HDL) Function in Metabolic Syndrome
Status: Enrolling
Updated: 3/22/2018
University of Connecticut
mi
from
Storrs, CT
Click here to add this to my saved trials
Fetuin-A Phosphorylation Status in Insulin Resistance and Metabolic Syndrome
Alterations in Phosphorylated Fetuin-A, a Novel Regulator of Insulin Action in Insulin Resistance and Metabolic Syndrome: Effects of Lifestyle Modification
Status: Enrolling
Updated:  3/23/2018
Auburn University
mi
from
Auburn, AL
Fetuin-A Phosphorylation Status in Insulin Resistance and Metabolic Syndrome
Alterations in Phosphorylated Fetuin-A, a Novel Regulator of Insulin Action in Insulin Resistance and Metabolic Syndrome: Effects of Lifestyle Modification
Status: Enrolling
Updated: 3/23/2018
Auburn University
mi
from
Auburn, AL
Click here to add this to my saved trials
Personalized Smartphone-assisted Coaching System to Improve Glucose Homeostasis in Adults With Prediabetes
Effectiveness of a Personalized Smartphone-assisted Coaching System to Improve Glucose Homeostasis in Adults With Prediabetes: Rationale and Study Protocol - Pilot Study
Status: Enrolling
Updated:  3/26/2018
Johns Hopkins Hospital
mi
from
Baltimore, MD
Personalized Smartphone-assisted Coaching System to Improve Glucose Homeostasis in Adults With Prediabetes
Effectiveness of a Personalized Smartphone-assisted Coaching System to Improve Glucose Homeostasis in Adults With Prediabetes: Rationale and Study Protocol - Pilot Study
Status: Enrolling
Updated: 3/26/2018
Johns Hopkins Hospital
mi
from
Baltimore, MD
Click here to add this to my saved trials
Personalized Smartphone-assisted Coaching System to Improve Glucose Homeostasis in Adults With Prediabetes
Effectiveness of a Personalized Smartphone-assisted Coaching System to Improve Glucose Homeostasis in Adults With Prediabetes: Rationale and Study Protocol - Pilot Study
Status: Enrolling
Updated:  3/26/2018
Reading Health System
mi
from
Reading, PA
Personalized Smartphone-assisted Coaching System to Improve Glucose Homeostasis in Adults With Prediabetes
Effectiveness of a Personalized Smartphone-assisted Coaching System to Improve Glucose Homeostasis in Adults With Prediabetes: Rationale and Study Protocol - Pilot Study
Status: Enrolling
Updated: 3/26/2018
Reading Health System
mi
from
Reading, PA
Click here to add this to my saved trials
Subcutaneous vs. Intramuscular Testosterone
Subcutaneous Testosterone Therapy in Men Compared to Intramuscular Testosterone Therapy in Men
Status: Enrolling
Updated:  3/26/2018
Men's Health Boston
mi
from
Chestnut Hill, MA
Subcutaneous vs. Intramuscular Testosterone
Subcutaneous Testosterone Therapy in Men Compared to Intramuscular Testosterone Therapy in Men
Status: Enrolling
Updated: 3/26/2018
Men's Health Boston
mi
from
Chestnut Hill, MA
Click here to add this to my saved trials
Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease
A Multicenter, Double-Masked, Placebo-Controlled, Efficacy And Safety Study Of RV 001, An Insulin-Like Growth Factor-1 Receptor (IGF-1R) Antagonist Antibody (Fully Human), Administered Every 3 Weeks (q3W) By Intravenous (IV) Infusion In Patients Suffering From Active Thyroid Eye Disease (TED)
Status: Enrolling
Updated:  3/27/2018
Jules Stein Eye Institute, UCLA
mi
from
Los Angeles, CA
Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease
A Multicenter, Double-Masked, Placebo-Controlled, Efficacy And Safety Study Of RV 001, An Insulin-Like Growth Factor-1 Receptor (IGF-1R) Antagonist Antibody (Fully Human), Administered Every 3 Weeks (q3W) By Intravenous (IV) Infusion In Patients Suffering From Active Thyroid Eye Disease (TED)
Status: Enrolling
Updated: 3/27/2018
Jules Stein Eye Institute, UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease
A Multicenter, Double-Masked, Placebo-Controlled, Efficacy And Safety Study Of RV 001, An Insulin-Like Growth Factor-1 Receptor (IGF-1R) Antagonist Antibody (Fully Human), Administered Every 3 Weeks (q3W) By Intravenous (IV) Infusion In Patients Suffering From Active Thyroid Eye Disease (TED)
Status: Enrolling
Updated:  3/27/2018
University of Denver
mi
from
Aurora, CO
Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease
A Multicenter, Double-Masked, Placebo-Controlled, Efficacy And Safety Study Of RV 001, An Insulin-Like Growth Factor-1 Receptor (IGF-1R) Antagonist Antibody (Fully Human), Administered Every 3 Weeks (q3W) By Intravenous (IV) Infusion In Patients Suffering From Active Thyroid Eye Disease (TED)
Status: Enrolling
Updated: 3/27/2018
University of Denver
mi
from
Aurora, CO
Click here to add this to my saved trials
Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease
A Multicenter, Double-Masked, Placebo-Controlled, Efficacy And Safety Study Of RV 001, An Insulin-Like Growth Factor-1 Receptor (IGF-1R) Antagonist Antibody (Fully Human), Administered Every 3 Weeks (q3W) By Intravenous (IV) Infusion In Patients Suffering From Active Thyroid Eye Disease (TED)
Status: Enrolling
Updated:  3/27/2018
Emory University Department of Ophthalmology
mi
from
Atlanta, GA
Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease
A Multicenter, Double-Masked, Placebo-Controlled, Efficacy And Safety Study Of RV 001, An Insulin-Like Growth Factor-1 Receptor (IGF-1R) Antagonist Antibody (Fully Human), Administered Every 3 Weeks (q3W) By Intravenous (IV) Infusion In Patients Suffering From Active Thyroid Eye Disease (TED)
Status: Enrolling
Updated: 3/27/2018
Emory University Department of Ophthalmology
mi
from
Atlanta, GA
Click here to add this to my saved trials
Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease
A Multicenter, Double-Masked, Placebo-Controlled, Efficacy And Safety Study Of RV 001, An Insulin-Like Growth Factor-1 Receptor (IGF-1R) Antagonist Antibody (Fully Human), Administered Every 3 Weeks (q3W) By Intravenous (IV) Infusion In Patients Suffering From Active Thyroid Eye Disease (TED)
Status: Enrolling
Updated:  3/27/2018
University of Iowa Hospitals and Clinics, Department of Ophthalmology
mi
from
Iowa City, IA
Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease
A Multicenter, Double-Masked, Placebo-Controlled, Efficacy And Safety Study Of RV 001, An Insulin-Like Growth Factor-1 Receptor (IGF-1R) Antagonist Antibody (Fully Human), Administered Every 3 Weeks (q3W) By Intravenous (IV) Infusion In Patients Suffering From Active Thyroid Eye Disease (TED)
Status: Enrolling
Updated: 3/27/2018
University of Iowa Hospitals and Clinics, Department of Ophthalmology
mi
from
Iowa City, IA
Click here to add this to my saved trials
Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease
A Multicenter, Double-Masked, Placebo-Controlled, Efficacy And Safety Study Of RV 001, An Insulin-Like Growth Factor-1 Receptor (IGF-1R) Antagonist Antibody (Fully Human), Administered Every 3 Weeks (q3W) By Intravenous (IV) Infusion In Patients Suffering From Active Thyroid Eye Disease (TED)
Status: Enrolling
Updated:  3/27/2018
Kellogg Eye Center at University of Michigan
mi
from
Ann Arbor, MI
Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease
A Multicenter, Double-Masked, Placebo-Controlled, Efficacy And Safety Study Of RV 001, An Insulin-Like Growth Factor-1 Receptor (IGF-1R) Antagonist Antibody (Fully Human), Administered Every 3 Weeks (q3W) By Intravenous (IV) Infusion In Patients Suffering From Active Thyroid Eye Disease (TED)
Status: Enrolling
Updated: 3/27/2018
Kellogg Eye Center at University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease
A Multicenter, Double-Masked, Placebo-Controlled, Efficacy And Safety Study Of RV 001, An Insulin-Like Growth Factor-1 Receptor (IGF-1R) Antagonist Antibody (Fully Human), Administered Every 3 Weeks (q3W) By Intravenous (IV) Infusion In Patients Suffering From Active Thyroid Eye Disease (TED)
Status: Enrolling
Updated:  3/27/2018
University of Nebraska Medical Center, Department of Ophthalmology
mi
from
Omaha, NE
Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease
A Multicenter, Double-Masked, Placebo-Controlled, Efficacy And Safety Study Of RV 001, An Insulin-Like Growth Factor-1 Receptor (IGF-1R) Antagonist Antibody (Fully Human), Administered Every 3 Weeks (q3W) By Intravenous (IV) Infusion In Patients Suffering From Active Thyroid Eye Disease (TED)
Status: Enrolling
Updated: 3/27/2018
University of Nebraska Medical Center, Department of Ophthalmology
mi
from
Omaha, NE
Click here to add this to my saved trials
Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease
A Multicenter, Double-Masked, Placebo-Controlled, Efficacy And Safety Study Of RV 001, An Insulin-Like Growth Factor-1 Receptor (IGF-1R) Antagonist Antibody (Fully Human), Administered Every 3 Weeks (q3W) By Intravenous (IV) Infusion In Patients Suffering From Active Thyroid Eye Disease (TED)
Status: Enrolling
Updated:  3/27/2018
Casey Eye Institute, Oregon Health & Science University
mi
from
Portland, OR
Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease
A Multicenter, Double-Masked, Placebo-Controlled, Efficacy And Safety Study Of RV 001, An Insulin-Like Growth Factor-1 Receptor (IGF-1R) Antagonist Antibody (Fully Human), Administered Every 3 Weeks (q3W) By Intravenous (IV) Infusion In Patients Suffering From Active Thyroid Eye Disease (TED)
Status: Enrolling
Updated: 3/27/2018
Casey Eye Institute, Oregon Health & Science University
mi
from
Portland, OR
Click here to add this to my saved trials
Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease
A Multicenter, Double-Masked, Placebo-Controlled, Efficacy And Safety Study Of RV 001, An Insulin-Like Growth Factor-1 Receptor (IGF-1R) Antagonist Antibody (Fully Human), Administered Every 3 Weeks (q3W) By Intravenous (IV) Infusion In Patients Suffering From Active Thyroid Eye Disease (TED)
Status: Enrolling
Updated:  3/27/2018
Hamilton Eye Institute, The University of Tennessee
mi
from
Memphis, TN
Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease
A Multicenter, Double-Masked, Placebo-Controlled, Efficacy And Safety Study Of RV 001, An Insulin-Like Growth Factor-1 Receptor (IGF-1R) Antagonist Antibody (Fully Human), Administered Every 3 Weeks (q3W) By Intravenous (IV) Infusion In Patients Suffering From Active Thyroid Eye Disease (TED)
Status: Enrolling
Updated: 3/27/2018
Hamilton Eye Institute, The University of Tennessee
mi
from
Memphis, TN
Click here to add this to my saved trials
Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease
A Multicenter, Double-Masked, Placebo-Controlled, Efficacy And Safety Study Of RV 001, An Insulin-Like Growth Factor-1 Receptor (IGF-1R) Antagonist Antibody (Fully Human), Administered Every 3 Weeks (q3W) By Intravenous (IV) Infusion In Patients Suffering From Active Thyroid Eye Disease (TED)
Status: Enrolling
Updated:  3/27/2018
Eye Wellness Center
mi
from
Houston, TX
Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease
A Multicenter, Double-Masked, Placebo-Controlled, Efficacy And Safety Study Of RV 001, An Insulin-Like Growth Factor-1 Receptor (IGF-1R) Antagonist Antibody (Fully Human), Administered Every 3 Weeks (q3W) By Intravenous (IV) Infusion In Patients Suffering From Active Thyroid Eye Disease (TED)
Status: Enrolling
Updated: 3/27/2018
Eye Wellness Center
mi
from
Houston, TX
Click here to add this to my saved trials
Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease
A Multicenter, Double-Masked, Placebo-Controlled, Efficacy And Safety Study Of RV 001, An Insulin-Like Growth Factor-1 Receptor (IGF-1R) Antagonist Antibody (Fully Human), Administered Every 3 Weeks (q3W) By Intravenous (IV) Infusion In Patients Suffering From Active Thyroid Eye Disease (TED)
Status: Enrolling
Updated:  3/27/2018
Medical College of Wisconsin, The Eye Institute
mi
from
Milwaukee, WI
Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease
A Multicenter, Double-Masked, Placebo-Controlled, Efficacy And Safety Study Of RV 001, An Insulin-Like Growth Factor-1 Receptor (IGF-1R) Antagonist Antibody (Fully Human), Administered Every 3 Weeks (q3W) By Intravenous (IV) Infusion In Patients Suffering From Active Thyroid Eye Disease (TED)
Status: Enrolling
Updated: 3/27/2018
Medical College of Wisconsin, The Eye Institute
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease
A Multicenter, Double-Masked, Placebo-Controlled, Efficacy And Safety Study Of RV 001, An Insulin-Like Growth Factor-1 Receptor (IGF-1R) Antagonist Antibody (Fully Human), Administered Every 3 Weeks (q3W) By Intravenous (IV) Infusion In Patients Suffering From Active Thyroid Eye Disease (TED)
Status: Enrolling
Updated:  3/27/2018
Johannes Gutenberg University Medical Center
mi
from
Mainz,
Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease
A Multicenter, Double-Masked, Placebo-Controlled, Efficacy And Safety Study Of RV 001, An Insulin-Like Growth Factor-1 Receptor (IGF-1R) Antagonist Antibody (Fully Human), Administered Every 3 Weeks (q3W) By Intravenous (IV) Infusion In Patients Suffering From Active Thyroid Eye Disease (TED)
Status: Enrolling
Updated: 3/27/2018
Johannes Gutenberg University Medical Center
mi
from
Mainz,
Click here to add this to my saved trials
Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease
A Multicenter, Double-Masked, Placebo-Controlled, Efficacy And Safety Study Of RV 001, An Insulin-Like Growth Factor-1 Receptor (IGF-1R) Antagonist Antibody (Fully Human), Administered Every 3 Weeks (q3W) By Intravenous (IV) Infusion In Patients Suffering From Active Thyroid Eye Disease (TED)
Status: Enrolling
Updated:  3/27/2018
Washington University Department of Ophthalmology
mi
from
Saint Louis, MO
Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease
A Multicenter, Double-Masked, Placebo-Controlled, Efficacy And Safety Study Of RV 001, An Insulin-Like Growth Factor-1 Receptor (IGF-1R) Antagonist Antibody (Fully Human), Administered Every 3 Weeks (q3W) By Intravenous (IV) Infusion In Patients Suffering From Active Thyroid Eye Disease (TED)
Status: Enrolling
Updated: 3/27/2018
Washington University Department of Ophthalmology
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Safety and Efficacy of Empiric Levothyroxine (LT4) Dose Increase Versus Individualized LT4 Dose Increase in Hypothyroid Women During Pregnancy
Randomized, Prospective Trial Comparing the Safety and Efficacy of Empiric Levothyroxine (LT4) Dose Increase Versus Individualized LT4 Dose Increase in Hypothyroid Women During Pregnancy
Status: Enrolling
Updated:  3/27/2018
MedStar Washington Hospital Center
mi
from
Washington,
Safety and Efficacy of Empiric Levothyroxine (LT4) Dose Increase Versus Individualized LT4 Dose Increase in Hypothyroid Women During Pregnancy
Randomized, Prospective Trial Comparing the Safety and Efficacy of Empiric Levothyroxine (LT4) Dose Increase Versus Individualized LT4 Dose Increase in Hypothyroid Women During Pregnancy
Status: Enrolling
Updated: 3/27/2018
MedStar Washington Hospital Center
mi
from
Washington,
Click here to add this to my saved trials
Intervening in Diabetes With Healthy Eating, Activity, and Linkages To Healthcare - The I-D-HEALTH Study
Community Translation of a Lifestyle Intervention to Improve Health in Diabetes
Status: Enrolling
Updated:  3/27/2018
YMCA of Metro Chicago
mi
from
Chicago, IL
Intervening in Diabetes With Healthy Eating, Activity, and Linkages To Healthcare - The I-D-HEALTH Study
Community Translation of a Lifestyle Intervention to Improve Health in Diabetes
Status: Enrolling
Updated: 3/27/2018
YMCA of Metro Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials